drugset / Trial / NCT03346135
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2
Active not recruiting
31 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well daratumumab after a stem cell transplant works in treating patients with multiple myeloma. Monoclonal antibodies, such as daratumumab, may kill cancer cells that are left after chemotherapy.
Timeline
- Start
- 2019-07-17
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | — | Intravenous |
| Background | Melphalan | Small molecule | — | — |